NCT06848231

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

A Double-Blind, Placebo-Controlled, Multi-Center, Phase II, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of YA-101 in Subjects With Multiple System Atrophy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (estimated)
• Sponsor: Dasher Neuroscience Inc. · Industry
• Sex: All
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.

Detailed description

The purpose of the study is to evaluate 2 doses of YA-101 compared to placebo in MSA patients, including: 1) safety and tolerability, 2) pharmacokinetics, and 3) potential efficacy of YA-101.

Conditions

• Multiple System Atrophy

Interventions

Type	Name	Description
DRUG	YA-101	Drug: YA-101 • YA-101 taken BID
DRUG	Placebo	Placebo taken BID

Timeline

• Start date: 2025-03-03
• Primary completion: 2026-06-30
• Completion: 2026-12-31
• First posted: 2025-02-26
• Last updated: 2025-09-10

Locations

9 sites across 3 countries: United States, Japan, Taiwan

Regulatory

• FDA-regulated drug study